Related Experiment Video
Updated: Jun 6, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Leptin and inflammation in patients with chronic heart failure
Ewa Straburzyńska-Migaj1, Adrian Gwizdała, Andrzej Siniawski
11st Department of Cardiology, Medical University, Poznań, Poland.
Insights
Elevated leptin levels in chronic heart failure (CHF) patients correlate with exercise capacity and inflammation markers. Higher leptin is linked to reduced peak oxygen uptake and increased ventilatory response, indicating a role in CHF pathophysiology.
Area of Science:
- Cardiology
- Endocrinology
- Exercise Physiology
Background:
- Leptin's role in cardiovascular pathophysiology, particularly its proinflammatory effects, is gaining interest.
- Elevated leptin levels are observed in non-cachectic chronic heart failure (CHF) patients, but its precise role remains unclear.
Purpose of the Study:
- To investigate the relationship between leptin levels in CHF patients with left ventricular (LV) systolic dysfunction.
- To assess correlations with ventilatory response to exercise and high-sensitivity C-reactive protein (hsCRP) levels.
Main Methods:
- Study included 41 stable CHF patients (LV ejection fraction < 45%) and 8 healthy controls.
- Cardiopulmonary exercise testing, echocardiography, and biochemical analyses (leptin, hsCRP, WBC) were performed.
Main Results:
- Leptin levels were significantly higher in CHF patients compared to controls (9.2 vs 2.9 ng/mL).
- Leptin correlated with BMI, waist circumference, leukocyte count, hsCRP, and inversely with peak VO₂.
- Multivariate analysis revealed VE/VCO₂ slope as independently associated with leptin levels.
Conclusions:
- Serum leptin levels are significantly related to exercise capacity (peak VO₂, VE/VCO₂ slope) in CHF patients.
- Leptin levels are also associated with inflammatory markers in this population.
Background:
There is an increasing interest in the role of leptin in cardiovascular pathophysiology, including proinflammatory effects. Many studies have reported elevated leptin levels in non-cachectic patients with chronic heart failure (CHF), however, the role of leptin in CHF remains unclear.
Aim:
To assess the relationship between leptin levels in patients with CHF and left ventricular (LV) systolic dysfunction in relation to ventilatory response to exercise and hsCRP levels.
Methods:
The study group consisted of 41 patients (mean age 50.2 ± 9.3 years) with stable CHF and LV ejection fraction < 45% and eight healthy controls (mean age 43.6 ± 14.7 years). Sixteen (39%) patients had coronary artery disease. All subjects underwent anthropometric measurements (weight, height, and waist circumference), standard echocardiography, and maximal cardiopulmonary exercise treadmill test. Biochemical analysis included the assessment of leptin and hsCRP levels as well as white blood count (WBC) and erythrocyte sedimention rate.
Results:
Leptin levels, including body mass index (BMI)-adjusted leptin levels, were significantly higher in the CHF patients than in the controls (9.2 ± 7.5 vs 2.9 ± 1.25 ng/mL; p = 0.005). We found significantly higher WBC, neutrophil count, lymphocyte percentage and BNP levels in the CHF group vs controls. There were significant correlations in the CHF group between leptin levels and BMI (r = 0.55; p < 0.05), waist circumference (r = 0.49; p < 0.05), leukocyte count (r = 0.41; p < 0.05), hsCRP levels (r = 0.34; p < 0.05), and peak VO₂ (r = -0.34; p < 0.05). Multivariate step forward regression analysis showed that peak VO₂ was significantly related with leptin levels. After adding VE/VCO₂ slope to the multivariate regression analysis model, only VE/VCO₂ slope was independently associated with leptin levels.
Conclusions:
There is a significant relationship between serum leptin levels and peak VO₂, VE/VCO₂ slope and levels of inflammatory markers in patients with CHF.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Heart Failure